SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	2 Months Ended	3 Months Ended			7 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2015 USD ($) ft² Customer $ / shares shares	Sep. 30, 2015 USD ($) ft² Customer $ / shares shares	Sep. 30, 2014 USD ($)	Mar. 31, 2012 USD ($)	Aug. 13, 2015 USD ($) ft² $ / shares shares	Sep. 30, 2015 USD ($) ft² Customer Payment Plan $ / shares shares	Sep. 30, 2014 USD ($) $ / shares shares	Dec. 31, 2014 USD ($) $ / shares shares
Cash, Cash Equivalents and Investments [Abstract]
Aggregate fair value of investments	$ 25,300,000	$ 25,300,000				$ 25,300,000		$ 12,200,000
Fair Value Disclosures [Abstract]
Held-to-maturity securities, unrecognized gain	0	0				0		0
Held-to-maturity securities, unrecognized loss	0	0				0		0
Concentration Risk [Line Items]
Accounts receivable	4,211,810	4,211,810				4,211,810		2,938,731
Royalty revenue		5,277,494	$ 3,484,975			15,574,234	$ 8,850,067
Deferred Revenue [Abstract]
Deferred revenue recognized		12,345	12,345			37,034	46,910
Deferred revenue balances	111,101	111,101				111,101		148,135
Milestones Revenue [Abstract]
Recognized milestone revenue		1,000,000	500,000			$ 1,000,000	$ 500,000
Treasury Stock [Abstract]
Treasury stock purchased (in shares) | shares						27,433	28,716
Average price of share (in dollars per share) | $ / shares						$ 43.07	$ 26.14
Reimbursable Third Party Development Costs [Abstract]
Accrued patent costs	15,000	15,000				$ 15,000		34,000
Third Party Royalties [Abstract]
Royalty expenses		300,000	200,000			1,000,000	$ 500,000
Royalty Buy-Down [Abstract]
Payment for royalty buy down				$ 1,500,000		$ 600,000
Number of additional cash payments for royalty buy down | Payment						5
Number of cash payments made for royalty obligation | Payment						2
Amount amortized related to agreement		221,000	61,000			$ 420,000	102,000
Deferred costs amortization period						5 years
Deferred royalty buy-down - long term	$ 3,400,000	$ 3,400,000				$ 3,400,000
Share-based Compensation [Abstract]
Number of stock based compensation plans in effect | Plan						1
Additional Disclosures [Abstract]
Proceeds from stock option exercises						$ 2,813,984	204,550
Closing price of Company stock (in dollars per share) | $ / shares	$ 43.54	$ 43.54				$ 43.54
Provision for Income taxes [Abstract]
Unrecognized tax benefits	$ 0	$ 0	0			$ 0	0
Commitments and Contingencies [Abstract]
Lease term					24 months
Monthly base rent	$ 10,213.20				$ 12,000
Area of of sublease to landlord | ft²	1,000	1,000			2,200	1,000
Additional lease term extension period	1 year
Notice period to cancel lease agreements	3 months
Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock granted during period, value of stock options						$ 450,000	123,000
Expected volatility rate						38.60%
Risk-free interest rate						1.41%
Expected life						6 years 3 months
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of property, plant and equipment						5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life of property, plant and equipment						10 years
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense		$ 33,000	5,000			$ 72,000	16,000
Accounts Receivables [Member] | Auxilium [Member]
Concentration Risk [Line Items]
Accounts receivable								$ 2,900,000
Number of customers | Customer	1	1				1
Accounts Receivables [Member] | Endo [Member]
Concentration Risk [Line Items]
Accounts receivable	$ 4,200,000	$ 4,200,000				$ 4,200,000
Number of customers | Customer	1	1				1
Revenues [Member] | Endo [Member]
Concentration Risk [Line Items]
Royalty revenue		$ 6,300,000	$ 4,000,000			$ 16,600,000	9,400,000
Stock Options [Member]
Stock Option Activity [Roll Forward]
Outstanding, beginning of period (in shares) | shares					759,958	759,958
Grants (in shares) | shares						30,000
Exercised (in shares) | shares						(217,958)
Forfeitures or expirations (in shares) | shares						0
Outstanding, end of period (in shares) | shares	572,000	572,000				572,000		759,958
Exercisable, end of period (in shares) | shares	514,500	514,500				514,500
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share) | $ / shares					$ 11.04	$ 11.04
Grants (in dollars per share) | $ / shares						37.64
Exercised (in dollars per share) | $ / shares						12.91
Forfeitures or expirations (in dollars per share) | $ / shares						0
Outstanding, end of period (in dollars per share) | $ / shares	$ 11.72	$ 11.72				11.72		$ 11.04
Exercisable, end of period (in dollars per share) | $ / shares	$ 9.44	$ 9.44				$ 9.44
Additional Disclosures [Abstract]
Weighted average remaining contractual term, Options outstanding						2 years 8 months 19 days		3 years 1 month 13 days
Weighted average remaining contractual term, grants						9 years 6 months 22 days
Weighted average remaining contractual term, Exercisable						2 years 2 months 8 days
Aggregate intrinsic value, Options outstanding					$ 23,483,235	$ 23,483,235
Aggregate intrinsic value, Options outstanding	$ 18,201,960	$ 18,201,960				18,201,960		$ 23,483,235
Aggregate intrinsic value, Exercisable	17,546,135	17,546,135				17,546,135
Proceeds from stock option exercises						2,800,000	$ 200,000
Unrecognized compensation cost related to non-vested stock options outstanding	$ 435,000	$ 435,000				$ 435,000
Recognized compensation period						3 years 4 months 28 days